Key takeaways
Muscle loss is not a side effect of tirzepatide (Zepbound, Mounjaro), but rapid or significant weight loss from tirzepatide may cause muscle loss.
Other potential causes of tirzepatide-related muscle loss include skipping resistance workouts due to fatigue and nausea, and having pre-existing risk factors like older age or low protein intake.
If you’re experiencing muscle loss after starting tirzepatide, talk to your healthcare provider to determine if the muscle loss is related to weight loss or if there might be an underlying health condition.
Here's what we'll cover
Here's what we'll cover
Here's what we'll cover
Key takeaways
Muscle loss is not a side effect of tirzepatide (Zepbound, Mounjaro), but rapid or significant weight loss from tirzepatide may cause muscle loss.
Other potential causes of tirzepatide-related muscle loss include skipping resistance workouts due to fatigue and nausea, and having pre-existing risk factors like older age or low protein intake.
If you’re experiencing muscle loss after starting tirzepatide, talk to your healthcare provider to determine if the muscle loss is related to weight loss or if there might be an underlying health condition.
If you’re considering using tirzepatide (Mounjaro or Zepbound) to support weight loss, you may have come across concerns about losing muscle along with body fat.
So, does tirzepatide cause muscle loss? Yes — though the picture is more nuanced than a simple yes or no. Significant weight loss — whether from tirzepatide or any other method — can reduce both fat and lean body mass, an umbrella term for muscles, organs, bones, and fluid. However, a substantial portion of the weight lost is typically body fat, and some research suggests muscle quality may improve, meaning the overall body composition may shift in a healthier direction.
Let’s take a closer look at tirzepatide muscle loss, including why it happens, what to do about it, and whether semaglutide vs. tirzepatide is more likely to cause it.
Does tirzepatide cause muscle loss?
Tirzepatide may cause some muscle loss simply by causing weight loss. Muscle loss is not listed as a side effect of tirzepatide, according to the prescribing information for Zepbound and Mounjaro. But tirzepatide can cause weight loss, and any significant or rapid weight loss can lead to muscle loss.
Here’s what the science says:
In clinical trials of tirzepatide, about 25% of the total weight lost came from lean mass, which includes muscle, organs, bones, and body fluids. The majority — roughly 75% — came from fat loss.
In one study, participants experienced reductions in muscle volume over time. However, these reductions were largely proportional to the amount of weight lost and similar to what’s seen with other weight loss methods.
In another study, people taking tirzepatide had smaller thigh muscle volume, but they also had significant reductions in fat stored within the muscle. This suggests that some of the change in muscle size may reflect improved muscle quality rather than harmful muscle loss.
Ultimately, even if you lose some muscle on tirzepatide, you may still see an overall improvement in body composition — because most weight loss tends to come from fat rather than muscle.
Why does tirzepatide cause muscle loss?
Losing a significant amount of weight quickly (whether with tirzepatide or any other method) can lead to muscle loss. People with obesity typically lose about 15% of their body weight on Zepbound, and about 25% of the total weight lost may come from lean mass.
Here are some potential causes of tirzepatide muscle loss:
Weight loss
Weight loss is the main driver of lean body mass loss in people taking tirzepatide. When body weight decreases, both fat and muscle can be lost. Rapid weight loss is even more likely to lead to lean mass loss, which includes muscle.
Wondering how tirzepatide works? As a dual GLP-1 and GIP receptor agonist, tirzepatide mimics two gut hormones that play roles in blood sugar regulation and appetite. Together, these effects slow down digestion, reduce appetite, and quiet cravings — which leads to significant weight loss in many people taking Mounjaro or Zepbound.
Side effects may reduce workout frequency
Fatigue and nausea are two common side effects of tirzepatide. And if you’re feeling tired and sick, you might be tempted to skip your regular workouts.
Over time, not using muscles can lead to muscle loss. The good news: muscle loss from reduced activity usually takes weeks to months to develop — and tirzepatide side effects tend to improve as your body adjusts to the medication.
Reduced protein intake
Tirzepatide decreases appetite, which can make it easy to eat much less overall — including less protein. When protein intake drops during weight loss, your body may reduce muscle protein synthesis and break down some lean tissue to meet its energy needs.
Eating enough protein each day can help support muscle preservation during weight loss.
Semaglutide vs. tirzepatide muscle loss: which causes more?
Research is too limited to say for sure if semaglutide (Wegovy, Ozempic) or tirzepatide causes more muscle loss. There have been no studies directly comparing their effects on muscle mass when administered simultaneously or at equivalent doses.
Tirzepatide tends to cause more overall weight loss than semaglutide. Since some lean mass is lost during any significant weight loss, greater total weight loss can mean greater absolute muscle loss. But that doesn’t mean tirzepatide is uniquely harmful to muscle — it likely reflects the larger drop on the scale.
With both medications, about 75–85% of weight lost is fat, and about 15–25% is lean mass. In other words, most of the weight loss comes from fat. Some research also suggests tirzepatide may reduce fat stored inside muscle, which could improve muscle quality.
Based on current evidence, both medications appear to affect muscle in proportion to the amount of weight lost — not because one directly damages muscle more than the other.
How to prevent tirzepatide muscle loss
Want to maintain muscle mass on tirzepatide? Strategies include eating plenty of protein, adding strength training to your workouts, and getting enough sleep.
1. Optimize protein intake
Getting enough protein is always important, but especially when you’re trying to lose weight. Protein helps you feel fuller after a meal, promotes fat loss, and helps preserve muscle mass.
Protein is found in animal sources like meat, eggs, and dairy, as well as plant-based sources such as soy, seeds, and lentils. A protein calculator can help you figure out how many grams of protein may be appropriate to target based on your individual goals — whether that’s weight loss, muscle preservation, or building muscle.
2. Do more strength training
Exercise is a helpful, healthy part of any weight management journey. Resistance training in particular has been shown to help prevent muscle loss during weight loss.
By adding strength training with free weights, resistance bands, or body-weight exercises to your workouts, you can set yourself up to preserve muscle mass while losing weight on tirzepatide.
3. Get enough sleep
Sleep might not sound like a muscle-building activity, but adequate rest is key to healthy body composition.
Getting 7–8 hours of sleep per night has been shown to help prevent muscle loss and promote fat loss. Research is also clear that even one night of poor sleep can undermine the body’s ability to repair and build muscle.
4. Maintain adequate calorie intake
Muscles need nourishment. Extreme calorie restriction can lead to greater muscle loss, which is why a slower, steadier approach to weight loss may help protect lean muscle mass.
Daily calorie needs vary from person to person. A calorie deficit calculator can help estimate how many calories may support weight loss while meeting nutritional needs. Prioritizing protein within that calorie range can also help protect lean muscle mass.
5. Incorporate daily movement
Strength training is important, but so is regular physical activity. One research review found that both resistance training and endurance exercises — such as running, biking, or brisk walking — are important for preserving muscle during weight loss.
Bottom line
Does tirzepatide cause muscle loss? Yes, tirzepatide can lead to some muscle loss — but that’s not the full picture. Let’s recap:
Weight loss from tirzepatide (or any other method) can cause muscle loss. Significant weight loss reduces fat and lean body mass, which includes muscle mass.
Quality is as important as quantity. In some studies, tirzepatide has also been linked to improvements in muscle quality, such as reduced fat stored within muscle tissue.
Proportions matter. Because fat loss is often greater than lean mass loss, some people taking tirzepatide may end up with a higher percentage of their body weight coming from muscle after treatment.
Semaglutide vs. tirzepatide muscle loss isn’t fully understood. No studies have directly compared muscle loss from semaglutide versus tirzepatide.
Muscle loss can be prevented. Muscle mass can be preserved or even built with strength training, a protein-rich diet, and other lifestyle strategies.
Muscle loss from tirzepatide isn’t always caused by the medication itself. Muscle loss from tirzepatide isn't always caused by the medication itself. Quitting your workout routine, eating too little protein, or losing weight very quickly can all contribute to muscle decline.
Frequently asked questions (FAQs)
Is muscle loss on tirzepatide permanent?
There’s no evidence that muscle loss on tirzepatide is permanent — or that it can’t be prevented or reversed with strength training and adequate protein intake. A study of semaglutide, another GLP-1 receptor agonist, found that the percentage of lean mass (which includes muscle mass) relative to total body mass actually increased, since GLP-1s preferentially target fat loss.
Does semaglutide cause more muscle loss than tirzepatide?
There’s not enough data to confirm whether semaglutide or tirzepatide causes more muscle loss. Both medications result in lean mass loss proportional to total weight loss.
Can I build muscle while taking tirzepatide?
There’s no reason you can’t build muscle while taking tirzepatide. Regardless of whether you’re on weight loss medication, a combination of resistance training and protein-rich eating is the standard for building muscle.
Importantly, tirzepatide also reduces fat stored inside muscle, which may improve muscle quality as well.
Does tirzepatide cause muscle weakness?
Tirzepatide doesn’t directly cause muscle weakness. However, some people might feel weak due to rapid weight loss, reduced calorie intake, dehydration, or electrolyte changes from potential GI side effects such as diarrhea or vomiting. If your weakness is severe or isn’t getting better with time, speak to your healthcare provider.
Does Zepbound cause muscle wasting?
Zepbound doesn't directly cause muscle wasting, but significant weight loss — a common outcome for people taking Zepbound — can reduce lean body mass, which includes muscle. Research suggests that skeletal muscle is largely preserved during tirzepatide treatment, though factors like reduced activity or low protein intake can contribute to muscle loss over time.
How do you make sure you don’t lose muscle on Zepbound?
The best ways to protect muscle while taking Zepbound are resistance training, eating enough protein, and prioritizing sleep — all of which have been shown to help prevent muscle loss during weight loss. If you're not sure where to start, your healthcare provider can help guide your next steps.
DISCLAIMER
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
Mounjaro Important Safety Information: Read more about serious warnings and safety info.
Zepbound Important Safety Information: Read more about serious warnings and safety info.
GLP-1 Important Safety Information: Read more about serious warnings and safety info.
References
Alissou, M., Demangeat, T., Folope, V., et al. (2026). Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes, Obesity & Metabolism, 28(1), 112–121. doi: 10.1111/dom.70141. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12673431/#dom70141-sec-0023
Aronne, L. J., Sattar, N., Horn, D. B., et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38–48. doi: 10.1001/jama.2023.24945. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10714284/
Cava, E., Yeat, N. C., & Mittendorfer, B. (2017). Preserving Healthy Muscle during Weight Loss. Advances in Nutrition (Bethesda, Md.), 8(3), 511–519. doi: 10.3945/an.116.014506. Retrieved from https://pubmed.ncbi.nlm.nih.gov/28507015/
Encarnação, I. G. A., Viana, R. B., Soares, S. R. S., et al. (2022). Effects of Detraining on Muscle Strength and Hypertrophy Induced by Resistance Training: A Systematic Review. Muscles, 1(1), 1-15. doi: 10.3390/muscles101000. Retrieved from https://www.mdpi.com/2813-0413/1/1/1
Fielding, R. A., Vellas, B., Evans, W. J., et al. (2011). Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. Journal of the American Medical Directors Association, 12(4), 249–256. doi: 10.1016/j.jamda.2011.01.003. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC3377163/
Gonzalez-Rellan, M. J. & Drucker, D. J. (2024). New Molecules and Indications for GLP-1 Medicines. JAMA, 334(14), 1231-1234. doi: 10.1001/jama.2025.14392. Retrieved from https://jamanetwork.com/journals/jama/article-abstract/2838996
Hardy, E. J. O., Inns, T. B., Hatt, J., et al. (2022). The time course of disuse muscle atrophy of the lower limb in health and disease. Journal of Cachexia, Sarcopenia and Muscle, 13(6), 2616–2629. doi: 10.1002/jcsm.13067. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9745468/
Hidalgo Ramos, R. A., Hong, I., Ortiz, M., et al. (2025). Effects of Tirzepatide on Skeletal Muscle Mass in Adults: A Systematic Review. Cureus, 17(7), e89020. doi: 10.7759/cureus.89020. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12394919
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine, 387(3), 205–216. doi: 10.1056/NEJMoa2206038. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
Karagiannis, T., Malandris, K., Avgerinos, I., et al. (2024). Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia, 67(7), 1206-1222. doi: 10.1007/s00125-024-06144-1. Retrieved from https://pubmed.ncbi.nlm.nih.gov/38613667
Kim, K., Shin, D., Jung, G. U., et al. (2017). Association between sleep duration, fat mass, lean mass and obesity in Korean adults: the fourth and fifth Korea National Health and Nutrition Examination Surveys. Journal of Sleep Research, 26(4), 453–460. doi: 10.1111/jsr.12504. Retrieved from https://pubmed.ncbi.nlm.nih.gov/28220551/
Lamon, S., Morabito, A., Arentson-Lantz, E., et al. (2021). The effect of acute sleep deprivation on skeletal muscle protein synthesis and the hormonal environment. Physiological Reports, 9(1), e14660. doi: 10.14814/phy2.14660. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785053/
Leidy, H. J., Clifton, P. M., Astrup, A., et al. (2015). The role of protein in weight loss and maintenance. The American Journal of Clinical Nutrition, 101(6), 1320S–1329S. doi: 10.3945/ajcn.114.084038. Retrieved from https://www.sciencedirect.com/science/article/pii/S0002916523274274
Look, M., Dunn, J. P., Kushner, R. F., et al. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity & Metabolism, 27(5), 2720–2729. doi: 10.1111/dom.16275. Retrieved from https://pubmed.ncbi.nlm.nih.gov/39996356/
Marsh, K. A., Munn, E. A., & Baines, S. K. (2013). Protein and vegetarian diets. The Medical Journal of Australia, 199(S4), S7–S10. doi: 10.5694/mja11.11492. Retrieved from https://pubmed.ncbi.nlm.nih.gov/25369930/
Martin, C. K., Carmichael, O. T., Carnell, S., et al. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nature Medicine, 31(9), 3141-3150. doi: 10.1038/s41591-025-03774-9. Retrieved from https://pubmed.ncbi.nlm.nih.gov/40555748
Martínez-Gómez, M. G. & Roberts, B. M. (2022). Metabolic Adaptations to Weight Loss: A Brief Review. Journal of Strength and Conditioning Research, 36(10), 2970–2981. doi: 10.1519/JSC.0000000000003991. Retrieved from https://pubmed.ncbi.nlm.nih.gov/33677461/
McCarthy, D. & Berg, A. (2021). Weight Loss Strategies and the Risk of Skeletal Muscle Mass Loss. Nutrients, 13(7), 2473. doi: 10.3390/nu13072473. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8308821/
MedlinePlus. (2025). Types of muscle tissue. Retrieved from https://medlineplus.gov/ency/imagepages/19841.htm
Mima, A. & Horii, Y. (2024). Tirzepatide Reduces Fat Mass and Provides Good Glycaemic Control in Type 2 Diabetes Patients Undergoing Haemodialysis: A Single-Centre Retrospective Study. Endocrinology, Diabetes & Metabolism, 7(3), e489. doi: 10.1002/edm2.489. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11078529/
Nuijten, M. A. H., Eijsvogels, T. M. H., Monpellier, V. M., et al. (2022). The magnitude and progress of lean body mass, fat-free mass, and skeletal muscle mass loss following bariatric surgery: A systematic review and meta-analysis. Obesity Reviews: An Official Journal of the International Association for the Study of Obesity, 23(1), e13370. doi: 10.1111/obr.13370. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285034/
Sardeli, A. V., Komatsu, T. R., Mori, M. A., et al. (2018). Resistance Training Prevents Muscle Loss Induced by Caloric Restriction in Obese Elderly Individuals: A Systematic Review and Meta-Analysis. Nutrients, 10(4), 423. doi: 10.3390/nu10040423. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946208/
Sargeant, J. A., Henson, J., King, J. A., et al. (2019). A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. Endocrinology and Metabolism (Seoul, Korea), 34(3), 247–262. doi: 10.3803/EnM.2019.34.3.247. Retrieved from https://e-enm.org/journal/view.php?doi=10.3803/EnM.2019.34.3.247
Sattar, N., Neeland, I. J., Dahlqvist Leinhard, O., et al. (2025). Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. The Lancet. Diabetes, 13(6), 482-493. doi: 10.1016/S2213-8587(25)00027-0. Retrieved from https://pubmed.ncbi.nlm.nih.gov/40318682/
Schoenfeld, B. J., Grgic, J., & Krieger, J. (2019). How many times per week should a muscle be trained to maximize muscle hypertrophy? A systematic review and meta-analysis of studies examining the effects of resistance training frequency. Journal of Sports Sciences, 37(11), 1286–1295. doi: 10.1080/02640414.2018.1555906. Retrieved from https://pubmed.ncbi.nlm.nih.gov/30558493/
U.S. Food & Drug Administration (FDA-a). (2026). Highlights of Prescribing Information: Mounjaro (tirzepatide) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s009lbl.pdf
U.S. Food & Drug Administration (FDA-b). (2026). Highlights of Prescribing Information: Zepbound(tirzepatide) injection, for subcutaneous use. Retrieved from
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf
Weiss, E. P., Jordan, R. C., Frese, E. M., et al. (2017). Effects of Weight Loss on Lean Mass, Strength, Bone, and Aerobic Capacity. Medicine and Science in Sports and Exercise, 49(1), 206–217. doi: 10.1249/MSS.0000000000001074. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161655/














